| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910832992803321 |
|
|
Titolo |
EIB Global Report 2022/2023 - The impact / EUROPEAN INVESTMENT BANK |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
[s.l.] : , : European Investment Bank, , 2023 |
|
|
|
|
|
|
|
Descrizione fisica |
|
|
|
|
|
|
Soggetti |
|
Business & Economics / Accounting / Financial |
Economics |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Sommario/riassunto |
|
Building on decades of experience working in Europe's neighbourhood, in Africa and around the world, under EU mandates and in support of EU policy priorities, EIB Global brings together all the financial, engineering and scientific expertise of the European Investment Bank to maximise impact. The new structure fosters strong, focused partnerships within Team Europe, with multilateral development banks and bilateral development agencies. With a stronger presence on the ground, it increases our cooperation with partner countries, clients, EU Member States and other development finance institutions. This publication reports on the first year of EIB Global. The first section reviews the development context, looking at global macroeconomic development and the different regions where EIB Global operates: EU neighbourhood countries sub-Saharan Africa the Western Balkans and Türkiye Asia and the Pacific, and Latin America and the Caribbean The report then turns to the overarching priorities of EIB Global and the European Fund for Sustainable Development Plus, examining investment needs and describing the response by EIB Global: Climate change Jobs and inclusive growth The Global Gateway The final part brings together all the information on the results and impact of EIB Global operations and the financial and non-financial contribution we make. It covers: How we measure |
|
|
|
|
|
|
|
|
|
|
|
|
|
results and impact Expected results of new projects EIB Global's contribution to new projects Evidence on the EIB's crowding-in effect Carbon footprint exercise Macroeconomic impact modelling Results of completed projects Lending volumes List of operations signed in 2022 A companion volume to this report, EIB Global Report: The Story [insert link], delves deeper into the rationale for, and experience gained from, individual EIB Global projects. |
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910767551503321 |
|
|
Autore |
Belmaker Robert Haim |
|
|
Titolo |
Psychopharmacology Reconsidered : A Concise Guide Exploring the Limits of Diagnosis and Treatment / / by Robert Haim Belmaker, Pesach Lichtenberg |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Edizione |
[1st ed. 2023.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (218 pages) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Psychiatry |
Neurology |
Neuropharmacology |
Nervous system - Diseases |
Diagnosis |
Therapeutics |
Neurological Disorders |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di contenuto |
|
Intro -- Acknowledgements -- Contents -- Chapter 1: Introduction -- References -- Chapter 2: The Biochemical Basis for Psychopharmacology in the Brain Synapse: Are We Looking in the Right Place? -- Reference -- Chapter 3: Are DSM or ICD Diagnoses the Basis for Scientific Use of Psychopharmacologic Drugs? |
|
|
|
|
|
|
|
|
|
-- References -- Chapter 4: The Clinical Control Trial in Psychiatry: What It Is, What It Has Been, and Does It Have a Future? -- Post-hoc Analyses -- Acute Trials, Prevention Trials, "Survival Trials" and Crossover Trials -- The Role of the Clinical Trial in the Teaching of Psychopharmacology -- Individual Differences -- Advice for the Clinical Reader of Controlled Trials -- Add-On Vs. Placebo Controlled Trials -- The Role of Guidelines -- Pathways for the Future -- References -- Chapter 5: Antidepressant Drugs: For Anyone Sad or Only for the Melancholic Depressed? -- Maintenance Treatment with Antidepressants -- The Development of SSRIs AND SNRIs -- The Monoamine Theories of Depression -- Monoamine Oxidase Inhibitors -- Bipolar Depression -- Antidepressants in Panic Disorder -- Switching Antidepressants in Treatment Resistance -- Cortisol and Depression -- Side Effects -- Pregnancy and Lactation -- Animal Models and Depression Psychopharmacology -- Stimulants in Depression -- Antidepressants in Depression After Myocardial Infarction -- Antidepressants and COVID-19 -- Psychological Effects of Antidepressant Treatment -- Clinical Vignettes -- References -- Chapter 6: Antipsychotic Drugs: Do They Define Schizophrenia or Do They Blunt All Emotions? -- Rating Scales -- Pharmacodynamics -- The Disease Model -- Mechanisms of Action -- The Dopamine Hypothesis -- New Antipsychotics -- Philosophy of Antipsychotic Treatment -- Doses -- Side Effects -- Clinical Vignettes -- References. |
Chapter 7: Antianxiety Medications: Are They Addictive or Are They Mankind's Precious Heritage? -- Historical Background -- The Nonlinear Nature of Anti-anxiety Treatment -- Alcohol as a Proto Anti-anxiety Drug -- Non-barbiturate Sedatives -- Benzodiazepines -- The Mechanism of Action of Benzodiazepines -- The Z Drugs -- Comparison of Treatment of Anxiety with Benzodiazepines Vs. Antidepressants -- Side Effects -- Sleep Architecture -- Benzodiazepine Use in Psychiatry-Related Medicine -- Pregnancy and Lactation -- Clinical Vignettes -- References -- Chapter 8: Mood Stabilizers: Off the Gold Standard? -- Pharmacokinetics and Pharmacodynamics -- Efficacy of Lithium in Bipolar Disorder -- Carbamazepine -- Valproic Acid -- Mood Stabilizers -- Antipsychotics as Mood Stabilizers -- Administration of Lithium -- The Importance of Patient History -- Suicidality -- Individual Differences and Prediction of Lithium Response in Bipolar Disorder -- Toxicity -- Side Effects -- Polyuria and Polydipsia -- Tremor -- Mood Stabilizers in Schizoaffective Disorder -- Mood Stabilizers in Unipolar Depression Maintenance Therapy -- Is Lithium in any Sense Specific? -- Clinical Vignettes -- References -- Chapter 9: Electroconvulsive Therapy, Transcranial Magnetic Stimulation, Deep Brain Stimulation and tDCS -- TMS -- Deep Brain Stimulation (DBS) -- Transcranial Direct Stimulation of the Brain -- Clinical Vignettes -- References -- Chapter 10: Pain Medication and Opiate Addiction -- Treatment of Opiate Addiction -- Side Effects -- Causes of Opiate Addiction -- Clinical Vignettes -- References -- Chapter 11: Stimulant Drugs: Are They Specific for Attention Deficit Disorder or Are They Abused and Overused? -- The Specificity of Stimulants in ADHD -- Effectiveness of Stimulant Treatment in ADHD -- Side Effects of Stimulant Drug Treatment. |
Psychological Side Effects of Stimulant Treatment -- Comorbidity -- Use of Stimulants for Learning Enhancement -- Long Term Outcomes -- Non Monoamine-Releasing Stimulants -- Use of Stimulants in ADHD Diagnosed Adults -- Pregnancy and Lactation -- How Can Dopamine Enhancement Help with Hyperactivity and Dopamine Reduction Improve Psychosis? -- Vignettes -- References -- Chapter 12: Childhood Psychopharmacology: Modern Parent's Salvation or Danger to the Brains |
|
|
|
|
|
|
|
|
|
of the Future Generation? -- Enuresis -- Disruptive Mood Dysregulation Disorder -- Autism -- References -- Chapter 13: Drugs for Alzheimer's and Other Dementia: Are they Worth Anything? -- References -- Chapter 14: Drugs for Obsessive Compulsive Disorder: Could Such Obviously Psychological Disorders Have a Pharmacological Treatment? -- Clinical Treatment of OCD -- Side Effects of SSRI Treatment of OCD -- OCD Symptoms in Other Syndromes and in Childhood -- Clinical Vignettes -- References -- Chapter 15: Cannabis: A Useful Psychotropic for Pain, PTSD and Sleep or a Gateway to Schizophrenia? -- Rimonabant and Dronabinol -- Synthetic Cannabinoids -- References -- Chapter 16: Ketamine and Psychedelics in PTSD and Depression: The New Frontier or the New Pandemic? -- Introduction -- Ketamine -- MDMA (Ecstasy) -- Psilocybin -- LSD -- Mechanisms -- References -- Chapter 17: The Placebo Response in Psychopharmacology and the Use of Nutraceuticals in Clinical Psychopharmacology -- The Placebo Response in Psychopharmacology -- Neurotransmitter Precursors -- Omega - 3 Fatty Acids -- Inositol -- Folic Acid -- Niacin -- References -- Chapter 18: Sexual Psychopharmacology: Important Symptomatic Treatment in Depression and Anxiety? -- Erectile Dysfunction -- Side Effects -- Clinical Use -- Sildenafil Abuse -- Rapid Ejaculation (PE) -- Women and PDE-5 Inhibiters and SSRIs. |
Testosterone for Male and Female Sexual Dysfunction -- HRT -- Transgender Treatment -- Sexology, Psychopharmacology and Psychiatry -- Clinical Vignettes -- References -- Chapter 19: Neuropsychopharmacology: Huntington's, Parkinson's, Tardive Dyskinesia, Narcolepsy, Migraine, Tourette's and Schizophrenia-Like Psychosis of Epilepsy -- Huntington's -- Narcolepsy -- Parkinson's -- Tardive Dyskinesia -- Migraine -- Tourette's Syndrome -- Schizophrenia-like Psychosis of Epilepsy -- References -- Chapter 20: Medication for Eating Disorders: By Popular Demand? -- Obesity -- Anorexia Nervosa -- Bulimia -- Conclusions -- References -- Chapter 21: Pharmacological Treatment of Alcohol Abuse: A Short Chapter -- Introduction -- References -- Chapter 22: Is There a Potential for New Treatments in Psychopharmacology or Have We Picked All the Low Hanging Fruit? -- RHB -- PL -- References -- Chapter 23: Learning and Teaching Psychopharmacology: A resident's Point of View -- Antidepressants and Sexual Psychopharmacology -- Antipsychotics -- Mood Stabilisers -- OCD -- Anxiety -- Stimulants and Children -- Clinical Trials, Diagnosis, Placebo and the Future -- Concluding Remarks -- References -- Index. |
|
|
|
|
|
|
Sommario/riassunto |
|
This thought-provoking book covers the full range of psychopharmacologic practice in textbook fashion, offering a fresh and comprehensive self-examination. Unlike conventional texts of psychopharmacology, this text speaks directly to clinicians who have started to question the limitations of psychopharmacologic claims and the rigid confines of DSM-5 diagnoses. Drawing from their clinical and research experience as well as new literature, the well-published authors provide a new perspective that encourages readers to reevaluate established practices and embrace that medication is just one component of treatment and has limits. The book could be used by psychiatric residents in their course of study, by clinical psychology students taking a psychopharmacology course, or by psychiatrists curious to get a readable but comprehensive look at new critical viewpoints in psychopharmacology that have changed since they were taught. Many neuroscience students who are looking for a review of clinical effects to guide their basic research may also find the proposed text more useful than those texts that collate clinical trials. Current |
|
|
|
|
|
|
|
|
|
|
|
|
|
texts are for specialized scientists or are part of multi-authored texts which list drugs alphabetically with no conceptual framework, or books that pretend that each biochemical drug property has a clear and known clinical result presented in cartoon style. Some lesser known texts for psychology or nursing students are not authoritative. Others aimed at patients or families are too simplistic for clinicians. The authors’ goal was to create a unified text expressing their view of psychopharmacology, its evidence base, the unity of its essential principles, and its independence of DSM or ICD diagnosis. Several new history books describe the "rise and fall" of psychopharmacology, the corruption of big pharma and the failure of large controlled clinical trials. Psychopharmacology Reconsidered: A Concise Guide Exploring the Limits of Diagnosis and Treatment ensures that young clinicians are aware of and understand this critical zeitgeist but aware also of the essential core of psychopharmacology and the evidence upon which it rests. |
|
|
|
|
|
|
3. |
Record Nr. |
UNINA9910839300303321 |
|
|
Autore |
Cihon Joseph H |
|
|
Titolo |
Behavior Analytic Approaches to Promote Enjoyable Mealtimes for Autistics/Individuals Diagnosed with Autism and their Families [PDF] |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Wilmington, DE : , : Vernon Art and Science Inc., , 2022 |
|
©2023 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Edizione |
[1st ed.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (396 pages) |
|
|
|
|
|
|
Collana |
|
Cognitive Science and Psychology |
|
|
|
|
|
|
Altri autori (Persone) |
|
TereshkoLisa |
MarshallKimberly B |
WeissMary Jane |
|
|
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Autistic children - Behavior modification |
Autistic children - Nutrition |
Autism - Treatment |
Behavior therapy |
Food habits - Psychological aspects |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
"It has been estimated that 70% to 90% of individuals diagnosed with autism spectrum disorder (ASD) experience mealtime challenges (Volkert & Vaz, 2010). Most approaches to the treatment of mealtime challenges have focused on decreasing interfering mealtime behaviors through escape extinction (i.e., requiring consumption of food prior to meal termination) and other approaches that may be perceived as punitive by parents, individuals diagnosed with ASD, and other stakeholders. In recent years, there has been an increase in research on promoting enjoyable mealtimes for individuals diagnosed with ASD and their families. The purpose of this edited book is to provide a comprehensive review of these approaches for improving mealtime behaviors for individuals diagnosed with ASD, provide clinical recommendations for improving mealtime behaviors, and identify areas for future research."-- |
|
|
|
|
|
|
|
| |